Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 1.8% – Still a Buy?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shares traded up 1.8% during trading on Tuesday . The stock traded as high as $4.18 and last traded at $4.00. 77,890 shares were traded during mid-day trading, an increase of 143% from the average session volume of 32,010 shares. The stock had previously closed at $3.93.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Cyclerion Therapeutics Stock Performance

The company’s 50-day moving average price is $3.59 and its two-hundred day moving average price is $2.88. The stock has a market cap of $18.72 million, a PE ratio of -2.41 and a beta of 1.76.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its earnings results on Tuesday, August 4th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.10) by $6.69. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 87.96%. Equities research analysts forecast that Cyclerion Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cyclerion Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP purchased a new position in shares of Cyclerion Therapeutics during the 3rd quarter valued at about $31,000. BlackRock Inc. purchased a new stake in Cyclerion Therapeutics in the second quarter worth approximately $57,000. Braidwell LP bought a new position in Cyclerion Therapeutics during the second quarter valued at approximately $532,000. Finally, ADAR1 Capital Management LLC bought a new position in Cyclerion Therapeutics during the second quarter valued at approximately $1,013,000. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.